Also, in newly discovered pathogenic dendritic cells in the circulation of RA patients, tofacitinib suppressed the production of IL-1β, IL-8, and IL-13 significantly, and that of IL-6 non-significantly [24]. This evidence concerns the gene IL6 and rheumatoid arthritis.